News
NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback